Lixte Biotechnology Holdings, Inc. (LIXT)

Compare

1.1800

+0.0100

+(0.85%)

As of 9:30:02 AM EDT. Market Open.

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Pre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether “initiated” cells that carry mutat

GlobeNewswire 4 days ago

LIXT
+0.85%
LIXTW
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on LB-100's Potential in Enhancing Cancer Immunotherapies- -Two Breakthrough Publications in Medical Journals, EMBO and Cancer Discovery,Supporting LIXTE’s Clinical Trial Program- PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”

GlobeNewswire 8 days ago

LIXT
+0.85%
LIXTW
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form

-- As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company, today announced online publication of new pre-clinical data in BioXriv and International Journal of Pharmaceutics demonstrating how the Company’s lead clinical compound, LB-100, is converted into i

GlobeNewswire 25 days ago

LIXT
+0.85%
LIXTW
LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab -- PASADENA, CALIF., Feb. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Company’s

GlobeNewswire last month

LIXT
+0.85%
LIXTW
Lixte Biotechnology announces closing of $1.05M registered direct offering

LIXTE Biotechnology (LIXT) announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 434,784 shares of the company’s common stock at a purchase price of $2.415 per share. In addition, in a concurrent private placement, the company issued unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants have an exercise price of $2.29 per share and are exercis

TipRanks last month

LIXT
+0.85%
LIXTW
LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PASADENA, CALIF., Feb. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 434,784 shares of the Company’s common stock at a purchase price of $2.415 per share. In addition, in a concurrent private placement, the Company issue

GlobeNewswire last month

LIXT
+0.85%
LIXTW
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 434,784 shares of its common stock at a purchase price of $2.415 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company wi

GlobeNewswire last month

LIXT
+0.85%
LIXTW
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the “SEC”) of the Company’s Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the “Registration Statement”), as the Company no longer intends to pursue a public o

GlobeNewswire last month

LIXT
+0.85%
LIXTW
US Penny Stocks To Watch In December 2024

As the U.S. market anticipates the Federal Reserve's decision on interest rates, stock futures are pointing to a higher open, suggesting a potential rebound from recent downturns. For investors looking beyond large-cap stocks, penny stocks—often representing smaller or newer companies—remain an intriguing area of exploration despite their historical connotations. These stocks can offer hidden value when backed by strong financials and growth potential, and this article will highlight three...

Simply Wall St. 3 months ago

PSHG

LIXT
+0.85%
LIXTW
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Investor Summit Group, an independent organization focused on creating networking opportunities for the MicroCap and SmallCap community, has announced that presentations from the August 20 Microcap ...

ACCESS Newswire 6 months ago

DCGO

SOTK

CVKD
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Patent Covers Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent application number 16/467,721, titled, "Oxabicycloheptanes for Modulation of Immune Response,” for combining the Company’s LB-100 compound with v

GlobeNewswire 6 months ago

LIXT
+0.85%
LIXTW
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. (“Roche”) for treatment of unresponsive (MSI Low) metastatic colorectal cancer. As part of the clinical trial (NCT06012734, clinicaltrials.gov), LIXTE is providing its lead compound, L

GlobeNewswire 7 months ago

LIXT
+0.85%
LIXTW
LIXTE Biotechnology Provides Update On Recent Activities and Developments

-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy- -LIXTE to Present at Two Upcoming Investor Conferences- PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW),

GlobeNewswire 7 months ago

LIXT
+0.85%
LIXTW
LIXTE Biotechnology Holdings to Present at Two Investor Conferences

-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference- PASADENA, CALIF., Aug. 15, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will be presenting at two investor conferences: The Investor Summit Summer 2024 Virtual Conference Tuesday, August 20, 2024, at 2 p.m. EDT/

GlobeNewswire 7 months ago

LIXT
+0.85%
LIXTW
Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

NEW YORK, NY / ACCESSWIRE / August 14, 2024 /Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company ...

ACCESS Newswire 7 months ago

LIXT
+0.85%
LIXTW
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic

GlobeNewswire 9 months ago

LIXT
+0.85%
LIXTW
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic

GlobeNewswire 9 months ago

LIXT
+0.85%
LIXTW
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced online publication of new pre-clinical data in the journal EMBO Reports, showing that its lead compound, LB-100, can turn immunologically “cold” tumors “hot,” potentially enhancin

GlobeNewswire 9 months ago

LIXT
+0.85%
LIXTW
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO) Lixte Biotechnology Holdings, Inc. PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 year

GlobeNewswire 9 months ago

LIXT
+0.85%
LIXTW
LIXTE Biotechnology Holdings Provides Update on Recent Activities

Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality”Presentation at MedInvest Biotech and Pharma Investor ConferenceCo-Sponsorship/Presentation of Workshop at Harvard University’s Dana Farber Cancer Institute PASADENA, CA, May 20, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new cla

GlobeNewswire 10 months ago

LIXT
+0.85%
LIXTW

Performance Overview

Return	LIXT	S&P 500 (^GSPC)
YTD	-41.87%	-11.47%
1-Year	-65.50%	+1.16%
3-Year	-90.33%	+13.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Lixte Biotechnology Holdings, Inc. (LIXT)

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form

LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Lixte Biotechnology announces closing of $1.05M registered direct offering

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

US Penny Stocks To Watch In December 2024

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Biotechnology Provides Update On Recent Activities and Developments

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

LIXTE Biotechnology Holdings Provides Update on Recent Activities

Performance Overview